Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Galapagos NV (GLPG) Ordinary Shares NPV (CDI)

Sell:€165.50 Buy:€165.70 Change: €7.05 (4.08%)
Market closed |  Prices as at close on 14 July 2020 | Switch to live prices |
Change: €7.05 (4.08%)
Market closed |  Prices as at close on 14 July 2020 | Switch to live prices |
Change: €7.05 (4.08%)
Market closed |  Prices as at close on 14 July 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company aims to develop a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. In addition, the Company’s mission is to develop a number of medicines based on the discovery of novel targets. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. Galapagos aims to develop small molecules that inhibit these targets, restore the balance and thereby positively influence the course of the disease.

Contact details

Generaal De Wittelaan 3
+32 (15) 342900

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€10.80 billion
Shares in issue:
64.82 million
Euronext Amsterdam
Amsterdam Exchanges Index

Key personnel

  • Onno van de Stolpe
    Chairman of the Executive Committee, Chief Executive Officer, Executive Director
  • Bart Filius
    Member of the Executive Committee, Chief Financial Officer, Chief Operating Officer
  • Piet Wigerinck
    Member of the Executive Committee, Chief Scientific Officer
  • Michele Manto
    Chief Commercial Officer
  • Walid Abi-Saab
    Member of the Executive Committee, Chief Medical Officer
  • Andre Hoekema
    Member of the Executive Committee, Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.